Background Two-thirds of people with dementia live at home supported mainly by family carers. These carers frequently develop clinical depression or anxiety, which predicts care breakdown. We aimed to assess the clinical eff ectiveness (long-term reduction of depression and anxiety symptoms in family carers) and cost-eff ectiveness of a psychological intervention called START (STrAtegies for RelaTives).
Introduction
Two-thirds of people with dementia live at home, with their family providing most of their care. 1 About 40% of family carers of people with dementia have clinical depression or anxiety; others have substantial psychological symptoms. 2, 3 Carer psychological morbidity predicts care breakdown and care home admission. 4 The STrAtegies for RelaTives (START) psychological intervention for family carers has been the fi rst to show both clinical eff ectiveness (reduced anxiety and depressive symptoms, reduced depression caseness, and improved quality of life) and cost-eff ectiveness for family carers of people with dementia. 5, 6 These were short-term results (8 months) , and for how long these eff ects are sustained is unclear. Previous studies of family carers suggest that eff ects persist for 7-11 months. 7 A multicomponent intervention showed no eff ect at 4 months, but the eff ect at 1 year was sustained for another 2 years. 8 We therefore tested START's long-term primary hypothesis that this intervention would show clinical and cost-eff ectiveness for family carers' aff ective psychological symptoms 2 years after randomisation. We also examined clinical and cost-eff ectiveness for people with dementia. We prespecifi ed a primary shortterm outcome at 8 months and a primary long-term outcome at 24 months.
Methods

Study design and participants
START is a parallel-group, superiority, single-blind, randomised controlled trial, which recruited participants 2:1 to START intervention or treatment as usual (TAU) to allow for therapist clustering, and was undertaken in the UK at four sites. The methods have been reported in detail elsewhere. 5, 6 Eligible participants were self-identifi ed family carers providing support at least once per week to people with a clinical diagnosis of dementia, living in their own homes and referred in the previous year. Carers who were unable to give informed consent to the trial, or who were already in a trial of carer support or who lived more than 1·5 h from the researchers' base were excluded. We recruited participants through three mental health trusts and a tertiary neurology clinic. Ethics approval was obtained, and participants gave written, informed consent.
Randomisation and masking
Randomisation was stratifi ed by centre with random permuted blocks of diff erent sizes via an online computer-generated randomisation system from an independent clinical trials unit. Assessors were unaware of the randomisation status, but the trial participants knew their allocation.
Procedures
We developed the 8-session START manual-based, individual coping intervention for dementia family carers from the US Coping with Caregiving intervention. 9 We trained and supervised non-clinically trained psychology graduates to deliver START, and monitored intervention fi delity by devising checklists that rated the most important components of every session. Therapists (the psychology graduates) recorded one therapy session per participant selected randomly by the trial manager. This session was completed by a therapist in the same team who was not associated with that participant's intervention. An overall fi delity score for every session was then given by the assessor, from 1 (not at all) to 5 (very focused).
The full START intervention manual is in the appendix and can be used after training. START is also summarised in panel 1. Therapists were trained and supervised as a group with additional time available for individual support. The graduate therapists were encouraged to be empathetic, adhere to the intervention, and to work with carers to fi nd answers rather than give solutions or advice. Together they identifi ed individual diffi culties and implemented strategies including relaxation, behavioural management, communication strategies, identifi cation and changing of unhelpful thoughts, positive reframing, accessing of emotional support, future planning, and increasing occurrence of pleasant events.
Every session fi nished with a relaxation session using a tailored CD. We asked carers to practise the strategies from the manual and listen to the relaxation CDs between sessions. The fi nal session included the development of a maintenance plan of useful strategies. Sessions were usually in participants' homes, unless they preferred the team's offi ce.
TAU within the health-care trusts connected with the trial was based on National Institute for Health and Care Excellence (NICE) guidelines, 10 with services based around the person with dementia. TAU is medical, psychological, and social, and is supposed to consist of assessment, diagnosis and information-giving, risk assessment and management (eg, assessments of risk of fi re, driving standards, adequate nutrition and selfcare, vulnerability, and management of money), drug treatment, cognitive-stimulation therapy, practical support, treatment of neuropsychiatric and cognitive symptoms, assessment of capacity to make long-term decisions and help given to make them, and carer support. We judged that the health trusts in our study had high TAU standards.
Outcomes
After the trial started, with funding body approval (while the database was locked), we agreed that the primary outcome should be Hospital Anxiety and Depression Scale total score (HADS-T) because this has better sensitivity and positive predictive value than the anxiety or depression score for identifying depression. 11 The primary outcomes were HADS-T 2 years after randomisation and cost-eff ectiveness (health and social care perspectives) over 24 months. The same primary outcomes were also assessed after 8 months for the short-term eff ects.
We obtained carer and patient sociodemographic details at baseline, and the following data at baseline, 4, 8, 12, and 24 months after randomisation: Therapists worked on a one-to-one basis with carers to identify individual diffi culties and implement strategies.
Carers kept their own manual and fi lled it in. Every session fi nished with a relaxation session. Carers were asked to practice the strategies and relaxation between sessions.
See Online for appendix For carers: Hospital Anxiety and Depression Scale (HADS), 11, 12 a validated, self-complete scale 11 summarised as HADS-D (depression) and HADS-A (anxiety) with scores from 0 to 21, and a total HADS score (HADS-T) from 0 to 42 (high scores are suggestive of more symptoms). HADS-D and HADS-A are also validated as scores for caseness, classifi ed as a case or non-case, with a cutoff point of 8-9; 11 Zarit Burden Interview 13 to adjust for baseline carer burden because carers with a high burden might be more stressed; Brief COPE, 14 a self-complete, coping strategies measure, validated in family dementia carers, 15 with subscales for diffi culty-focused, emotion-focused, and dysfunctional coping; Health Status Questionnaire (HSQ) 16, 17 that measures mental-health domain measures of quality of life; European quality of life fi ve dimensions questionnaire (EQ-5D) 18 that measures health status, generating a usefulness score; Client Service Receipt Inventory (CSRI) 19 that measures carer health and social care service use over 4 months retrospectively; and the Modifi ed Confl ict Tactics Scale (MCTS) that measures potentially abusive behaviour by carers towards care recipients. Ten behaviours, ranging from shouting to slapping, over the previous 3 months are rated from never (0) to all the time (4). A score of at least 2 for any item is classifi ed as abusive. 20 Carer's information about the patient: Clinical Dementia Rating (CDR) of dementia severity from very mild (0·5) to severe (3); 21 Neuropsychiatric Inventory (NPI) 22 to adjust for baseline NPI. High patient neuropsychiatric symptoms increase carer psychological morbidity; Quality of life-Alzheimer's Disease 23 that measures the quality of life for a patient with Alzheimer's; and a CSRI that retrospectively measures patient health and social care service use over 4 months.
We did not obtain data for adverse events, because we judged that such events, in terms of carers being unwell, would not be due to the therapy. We did obtain adverse outcomes in terms of costs, which are reported later in the Article.
Statistical analysis
This study was originally powered for a primary outcome of HADS anxiety score 5 needing a sample size of 90 in the control TAU group and 168 in START (participant allocation was unequal to allow for therapist clustering in START). When the primary outcome was changed to HADS-T, the sample then available (87 TAU, 173 START) was suffi cient to detect a mean diff erence in HADS-T of at least 2·4 points (with 80% power, 5% signifi cance) assuming an SD of 7·4 (as for pilot data), allowing for analysis of covariance (assumed correlation 0·5) and two repeated follow-up measurements (assumed correlation 0·7). A drop-out of 10% was assumed, and a design eff ect of 1·4 was applied for the START group (with an intracluster correlation coeffi cient of 0·03) 24 and an average cluster size of 15 carers per therapist).
In the primary analysis, we used regression methods to estimate group diff erences in long-term follow up (12 and 24 months) for HADS-T, treatment costs for carers, and quality-adjusted life-years (QALYs) calculated from European quality of life-5D measures with societal weights. 25 Random-eff ects models accounted for therapist clustering in the START group and measurements were repeated at 12 and 24 months. We adjusted results for baseline total score, centre (by which randomisation was stratifi ed), and factors known to have an eff ect on aff ective symptoms (patient age, sex, and NPI, and carer burden). For cost-eff ectiveness analyses, we adjusted for the same characteristics, plus prerandomisation costs. Non-parametric bootstrapping was used to estimate 95% CIs for mean costs because of skewed data. All analyses were by intention-to-treat but excluded carers with data missing at both 12 and 24 months. Because QALY estimation needs data at every timepoint, we included only complete cases for this analysis.
Sensitivity analyses for both clinical and economic outcomes were tested for robustness, with adjustments made fi rst for imbalances in baseline characteristics and second for predictors of missing outcomes. The eff ect of missing data was also addressed, for clinical outcomes, with a multiple-imputation method. By inclusion of interaction terms, we examined possible diff erential eff ects of treatment at 12 and 24 months and fi tted models incorporating all repeated measurements, to explore diff erential treatment eff ects over both short-term (up to 8 months) and long-term (up to 24 months) periods.
Similar approaches were taken for cost-eff ectiveness and analysis of secondary outcomes. Random eff ects logistic regression was used for binary outcomes. START's eff ect on time until care home admission was examined with parametric, shared, frailty models, allowing for clustering in the START group and adjustment for baseline factors. Models had gamma distribution for shared frailty and Weibull distribution for time until care home admission.
Unit costs were set at 2009-10 prices. 26, 27 Costs and outcomes in the second year were discounted at 3·5%. 28 START intervention cost was calculated from therapist time spent in training, supervision, and intervention delivery. The relaxation CDs were costed at market rates for copying and delivery. 6 Costs were calculated separately for carers' and patients' service use, from a health and social care perspective. Costs for months 13 to 21 were estimated by interpolation from data obtained at 12 and 24 months to generate costs for the full period.
We calculated incremental cost-eff ectiveness ratios (diff erence in cost between START and TAU divided by diff erence in outcome) for carer plus patient costs and, in turn, two carer outcomes (HADS-T, quality-adjusted lifeyears) and one patient outcome (quality of lifeAlzheimer's Disease) over 24 months. We repeated these analyses for carer-only costs. In view of the uncertainty in estimation of costs and outcomes, we plotted cost-eff ectiveness acceptability curves using a net-benefi t approach across a range of willingness-to-pay values.
We used the STATA version 11 computer program to do the statistical analyses for the clinical outcomes, and STATA version 12 for the cost-eff ectiveness analyses. This trial is registered ISCTRN70017938.
Role of the funding source
The funder of the study had no role in study design, data collection, analysis, data interpretation, manuscript writing, or decision to submit for publication. GL, CC, JB, MK, RR, DK, DL, and MG had access to all the data. All authors had fi nal responsibility for the decision to submit for publication. 
Results
472 carers were referred to us for potential inclusion in our trial. Of these, 181 (38%) refused to take part, 22 (5%) did not meet inclusion criteria, and nine (2%) were not contactable. Those who consented were slightly more likely to be married to the patient than those who did not consent. 5 Therefore we randomly assigned 260 (55%) of 472 of the carers referred between Nov 4, 2009, to June 8, 2011 to one of the trial groups (fi gure 1). 173 (67%) participants were assigned to START intervention and 87 (33%) to TAU. Randomisation generally achieved good balance in terms of sociodemographic and clinical characteristics (table 1) .
130 (75%) carers in the intervention group attended at least fi ve therapy sessions, eight (5%) withdrew before any therapy sessions. Each of ten therapists (seven women) delivered the intervention to between 11 and 32 carers, with a mean fi delity score of 4·7/5 (SD 0·66). Primary clinical analyses included 209 (80·4%) participants with HADS-T data at 12 or 24 months. Table 2 shows the primary outcomes. Analysis of HADS-T at 24 months, adjusting for centre, baseline score, and factors related to outcome (carer age and sex, NPI, Zarit) showed a mean diff erence of -2·58 points (95% CI -4·26 to -0·90; p=0·003) in favour of START.
In the model not including outcome-related factors, mean HADS-T decrease was -1·84 (95% CI -3·50 to -0·17; p=0·03). Sensitivity analyses adjusting for relevant predictors of missing HADS-T scores (coresidence with carer and a high COPE dysfunction score) showed a mean diff erence of -2·69 (95% CI -4·39 to -0·98, p=0·002, n=200), and adjustment for baseline imbalances (carer work, carer education, patient education, relationship with carer, and living with carer) showed a mean diff erence of -2·37 (-4·11 to -0·63, p=0·008). Results were also similar after multiple imputation (-2·28; -3·94 to -0·63, n=260).
Models including interaction with time showed no evidence of diff erential eff ects at 12 or 24 months (p=0·76). Short (up to 8 months) and long-term eff ects (12 to 24 months) showed no diff erences (p=0·92).
Signifi cantly fewer cases of HADS-depression occurred in START compared with TAU (odds ratio [OR] 0·14, 95% CI 0·04-0·53). The diff erence in HADS-anxiety caseness was not signifi cant (OR 0·57, 0·26-1·24).
Adjusted models for HADS-anxiety and HADSdepression continuous scores showed signifi cant benefi cial intervention eff ects over 24 months with START, with mean decreases of -1·16 (95% CI -2·15 to -0·18, n=200) and -1·45 (-2·32 to -0·57), respectively. Models showed no evidence of diff erential intervention eff ects with time for HADS-anxiety or HADS-depression (p=0·99 and p=0·86, respectively).
START Mean therapy cost was £232 per carer. When adjusted for baseline characteristics, carer-service costs were slightly higher in the START group than in the TAU group, but not signifi cantly diff erent between groups from 1 to 24 months (£170; 95% CI -132 to 472), and patient-service costs were lower in START than in TAU, but were also not signifi cantly diff erent between the groups over the same period (-£1368; 95% CI -5027 to 2291; table 3).
Cost-eff ectiveness analyses included carer-only costs and carer-and-patient costs combined. Sample sizes in cost-eff ectiveness analyses are smaller because of missing values.
In the main analyses with combined costs (table 4) , START dominates TAU when looking at carer outcomes (HADS-T and quality-adjusted life-years), because outcomes are better and costs not signifi cantly diff erent.
For the second primary outcome of cost-eff ectiveness (with quality-adjusted life-years as an outcome [fi gure 2]), START is cost eff ective with respect to NICE thresholds (67% probability of cost-eff ectiveness at £20 000 per quality-adjusted lifeyear willingness-to-pay threshold; 70% at £30 000 threshold). 28 For patient quality of life-Alzheimer's Disease measures, neither cost nor outcome was signifi cantly diff erent between the groups. In view of uncertainty in the analyses, cost-eff ectiveness acceptability curves were plotted. For quality of life-Alzheimer's Disease measures, the curve suggests a high probability of cost-eff ectiveness (fi gure 2) at all willingness-to-pay values. For HADS-T, the curve again shows a high probability of costeff ectiveness for the intervention (appendix) across all willingness-to-pay values, although there is no externally recommended threshold.
When looking only at carer-only costs, the pattern of cost-eff ectiveness is little changed (table 4). Cost per QALY is now £12 400, again less than the NICE threshold. From a health and social care perspective, cost-eff ectiveness analyses using combined costs are more relevant.
To assess the robustness of these fi ndings, we adjusted the results for relevant predictors of missing data, which gave similar results-the intervention having a 67% likelihood of cost-eff ectiveness at the NICE £20 000 per quality-adjusted life-year threshold (75% at £30 000 threshold). For the second sensitivity analysis with adjustments for baseline characteristics imbalances, mean incremental cost-eff ectiveness ratios (ICERs) change (table 4) , as does the pattern of probability of costeff ectiveness across the willingness-to-pay range (see appendix). The change in the ICER for the quality-adjusted life-year outcome is exaggerated by the very small betweengroup diff erence, but the eff ect on the cost-eff ectiveness acceptability curve is slight-eg, at £20 000 willingness-topay threshold, START has a 50% likelihood of being cost eff ective. With respect to HADS-T, START has more than a 50% likelihood of cost-eff ectiveness at all willingness-topay values. With respect to patient quality-of-life measures for Alzheimer's Disease, the case for START's costeff ectiveness is weaker in the sensitivity analysis; when 
Outcomes used in economic evaluation
Carer:
Data are mean (SD), n (%), or diff erence (95% CI) (sample size). TAU=treatment as usual.START=STrAtegies for RelaTives. EQ5D=European quality of life fi ve dimensions questionnaire. QALY=quality-adjusted lifeyear. HADS-T=Hospital Anxiety and Depression Scale-Total score. QOL-AD=Quality of Life-Alzheimer's Disease. *Not adjusted for any baseline scores or centre. †For carers, diff erences adjusted for baseline score, centre, age, sex, Neuropsychiatric Inventory, and the Zarit Burden Interview. Outcomes also adjusted for baseline total carer cost. For patients, diff erences adjusted for baseline score, centre, patient's age, sex, NPI, and carer's Zarit. Outcomes are also adjusted for baseline total patient costs. including carer-only costs, the cost per quality-adjusted life-year becomes £23 267 (table 4) .
Discussion
START, a structured psychological intervention for family carers of people with dementia, improved carers' depression and anxiety symptoms and quality of life not only in the short term, but also up to 24 months later. This is the fi rst trial to show such results (panel 2). 29 The magnitude of diff erence in the total HADS symptoms is in the range that is important to patients and is clinically signifi cant compared with other clinically meaningful changes. 30 Similarly, the quality of life diff erence between the START and TAU groups is the same magnitude as that between depressed and non-depressed community residents.
17 At 2 year follow-up, carers in the control TAU group were seven times more likely to have clinically signifi cant depression than in the START intervention group-this result is by defi nition clinically signifi cant. START is also cost eff ective over both short and long term. Both community social care and care-home costs rose over time for the patients with dementia in both groups, as a result of worsening dementia. Care-home costs increased in both groups, with a greater increase in TAU than START, although this result was not signifi cantly diff erent. We are monitoring care-home admissions for another 5 years.
Previous successful interventions for aff ective disorders in family carers show that coping strategies and individual (rather than group) therapy could be eff ective for depressive symptoms, but little evidence exists for their eff ect on anxiety. Previous studies have neither included prevention as an outcome, nor fully measured cost-eff ectiveness; a review showed some evidence that interventions could generate savings, 31 and a similar intervention to START showed a signifi cant diff erence in carer-time inputs over 6 months. 32 Family carers become more anxious and depressed over time without an intervention; thus we did not exclude carers who were not depressed at the beginning of the study. 33, 34 START's preventive eff ect underlines the fact that carers can benefi t from early intervention.
A strength of our study was that carers were heterogeneous in sociodemographic and clinical characteristics, and recruited from varied services. Most patients had mild dementia at baseline, making the intervention generally acceptable to and applicable to family carers around the time UK patients present to secondary care with dementia. Limitations include the possibility of response bias in those who agreed to the study; because carer and patient morbidity levels were slightly higher than another cohort of newly referred people with dementia, 35 those with more diffi culties might have been more likely to consent to participate this trial. However, because the interventions in this study both prevented and treated depression, this therapy is likely to be applicable to those not in the investigation.
36
Panel 2: Research in context
Systematic Review
Before this study, we systematically reviewed evidence for family carer interventions for anxiety and depression using quality guidelines to prioritise high-quality evidence and combining it according to the type of intervention. 2, 30 We searched the electronic databases Allied and Complementary Medicine, British Nursing Index, CINAHL(R), Embase, Medline, the Cochrane systematic review database, and reference lists from articles, until June, 2005. We noted that interventions up to now had been delivered by highly trained clinicians, usually psychologists. The most eff ective therapies were multicomponent, needed active participation of the carer, were tailored to individual carers, and delivered individually. They sometimes, over many years, delayed admission of people with dementia to a care home.
Interpretation
On the basis of our trial results we suggest that STrAtegies for RelaTives (START) is a clinical and cost-eff ective intervention to treat and prevent depression and anxiety in family carers of people with dementia. This is the fi rst time that these results have been shown to continue long-term (2 years). START is also cost-eff ective for people with dementia, and these eff ects also continue over 2 years. There is no other rigorous study of an intervention delivered by psychology graduates without previous clinical training, and no other extensive studies of cost-eff ectiveness. Previous studies of similar interventions in the USA have shown results consistent with ours, but our intervention might be more practical for many carers, because they did not need to all attend a group at the same time. Trials of psychosocial interventions in Europe (UK, Denmark, and Norway) using diff erent models have been ineff ective in terms of carers' psychological symptoms and quality of life, thus showing that our results were not attributable solely to a therapist off ering time and attention. Future studies should assess the eff ects of carer interventions on people with dementia in terms of clinical outcomes (ie, cognition and neuropsychiatric symptoms), and in the longer-term, care-home admission-we have extended our study for this latter aim. Additionally, we wish to further analyse the eff ect of carer interventions on abuse, especially the interaction between abuse and carehome admissions-abuse can lead to admission, and interventions for carers such as START could prevent further abuse and admissions. The trial was not powered for the economic evaluation, which could account for the non-signifi cance of those diff erences. Follow-up showed a slight bias; adjustment for the bias suggested that START was slightly more cost eff ective and clinically eff ective than the primary analysis. We minimised bias with standard measures validated for this population, independent randomisation, and follow-up assessors who were unaware of the allocation, although family carer participants inevitably knew the group allocation. At 2 years, the follow-up rate was 80% and sensitivity analyses showed similar results.
High fi delity ratings and very low intercluster correlations indicate that the results do not diff er between therapists, suggesting that START can be delivered consistently. START is multifaceted because these interventions are more likely to work in complex situations; qualitative follow-up substantiated our idea that carers used diff erent components of the intervention. 37 However, therapists saw most people at their homes (153 of 173) and were more fl exible in timing than most NHS non-emergency services-eg, seeing 19 of 173 participants in the evenings. Our evidence for costs and costeff ectiveness for this method of delivery at home suggests that it should be feasible to provide in this format.
In conclusion, the START intervention is clinically eff ective in the long term, improving carer mood and quality of life for 2 years. It does not raise costs, and it is cost eff ective in terms of both carer and patient outcomes, with respect to NICE cost thresholds.
Many countries face rapidly growing numbers of people with dementia, including single people, over the coming decades, and policy frameworks assume their families will remain frontline providers of (unpaid) support. Most people with dementia also prefer to receive support from family members. In these circumstances, a cost-neutral intervention such as START, which substantially improves family carer mental health and quality of life whether or not they live with the person with dementia, should be made widely available.
